RxDoctor Payments Data

Uzma Jalal, MD

Family Medicine · Plano, TXNPI 1316294036

Payments from drug & device makers

$1,557in general payments, 2019–2025

Across 85 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$236
  • AbbVie$194
  • Pfizer$150
  • Lilly USA, LLC$129
  • Novo Nordisk$125
  • Astellas Pharma US Inc$123
  • plus $600 from 15 others

What the payments were for

  • Food & beverage$1,557100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,557 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$80,572
Medicare patients
245
Services billed
1,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$69,175
MounjaroTirzepatide45$55,380
TrulicityDulaglutide30$45,329
JardianceEmpagliflozin24$37,031
EliquisApixaban31$35,913
JanuviaSitagliptin Phosphate25$33,087
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$17,719
SymbicortBudesonide/Formoterol Fumarate50$11,365
LinzessLinaclotide17$11,291
MyrbetriqMirabegron11$10,591
FarxigaDapagliflozin Propanediol11$9,074
Spiriva RespimatTiotropium Bromide16$8,657
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$4,702
Atorvastatin Calcium554$4,628
Gabapentin224$4,047

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$129$100,70975 claims
Novo NordiskOzempic$125$69,17567 claims
Boehringer IngelheimJardiance, Spiriva Respimat$30$45,68740 claims
PfizerEliquis$150$35,91331 claims
MerckJanuvia$31$33,08725 claims
AstraZenecaSymbicort, Farxiga$62$20,43961 claims
GSKTrelegy Ellipta$236$17,71924 claims
AbbVieLinzess, Synthroid$194$14,55761 claims
Astellas Pharma US IncMyrbetriq$123$10,59111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →